Search
Lonafarnib
go.drugbank.com/drugs/DB06448ApprovedInvestigationalHutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint c...
Phenaridine
go.drugbank.com/drugs/DB09178ExperimentalIllicitFentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue
Regramostim
go.drugbank.com/drugs/DB05386InvestigationalRegramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages. Endothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found a...
Milnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalMoreover, recent research has shown that the levorotatory enantiomer of milnacipran, levomilnacipran, may have the capacity to inhibit the activity of beta-site amyloid precursor protein cleaving enzyme
Maftivimab
go.drugbank.com/drugs/DB15899ApprovedInvestigational[A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.
Ulipristal
go.drugbank.com/drugs/DB08867ApprovedInvestigationalA recent systematic review proclaimed that the majority of available evidence demonstrates an inhibitory effect on ovulation rather than a post-fertilization effect on the endometrium, which has been heavily … It also binds to glucocorticoid receptor, however compared to mifepristone (a progesterone receptor antagonist), ulipristal is more tolerable and has lower glucocorticoid activity and better binding affinity
Categories: Progesterone Receptor Modulators, Selective Progesterone Receptor ModulatorsUbrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.
Categories: Calcitonin Gene-Related Peptide Receptor AntagonistsExercise
go.drugbank.com/conditions/DBCOND0029333Follitropin
go.drugbank.com/drugs/DB00066ApprovedInvestigationalHowever, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but
Casimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigational[A218186] Casimersen is the most recent in a line of approved PMOs for treating DMD, including [eteplirsen] and [viltolarsen].